Barinthus Biotherapeutics PLC. (BRNS) — SEC Filings
Barinthus Biotherapeutics PLC. (BRNS) — 30 SEC filings. Latest: DEFM14A (Apr 30, 2026). Includes 13 8-K, 5 10-Q, 2 8-K/A.
View Barinthus Biotherapeutics PLC. on SEC EDGAR
Overview
Barinthus Biotherapeutics PLC. (BRNS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: Barinthus Biotherapeutics plc reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $55.355 million, compared to $40.592 million for the same period in 2024. This 36.37% increase was primarily driven by a complete absence of license revenue in 2025, down
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant filing sentiment for Barinthus Biotherapeutics PLC. is neutral.
Filing Type Overview
Barinthus Biotherapeutics PLC. (BRNS) has filed 1 DEFM14A, 13 8-K, 5 10-Q, 2 8-K/A, 2 DEFA14A, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of BRNS's 23 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$55.355M |
| EPS | -$1.37 |
| Debt-to-Equity | 0.29 |
| Cash Position | $74.272M |
| Operating Margin | N/A |
| Total Assets | $109.201M |
| Total Debt | $24.640M |
Key Executives
- Enright
- Brown
- Griffiths
- Jonathan Jonathan
- Sarah Howell
- Dr. Sarah Gilbert
- Dr. Jonathan Milner
- Mr. David M. D. Smith
- Dr. Sarah Howell
- Dr. David Porter
- Dr. Jonathan Millson
Industry Context
Barinthus operates in the highly competitive biopharmaceutical sector, focusing on developing novel immunotherapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Companies often pursue strategic partnerships, mergers, or acquisitions to leverage complementary assets and accelerate pipeline development, as seen with the proposed merger with Clywedog Therapeutics.
Top Tags
financials (5) · corporate-action (3) · corporate-governance (3) · 10-Q (3) · biotech (3) · proxy-statement (3) · Biotechnology (2) · Net Loss (2) · Cash Burn (2) · amendment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $55.355M | Increased from $40.592M in 2024 for the nine months ended September 30, 2025 |
| License Revenue | $0 | Down from $14.969M in 2024 for the nine months ended September 30, 2025 |
| Impairment of long-lived assets | $4.667M | New expense in 2025 for the nine months ended September 30, 2025 |
| Cash and cash equivalents | $74.272M | Decreased from $110.662M at December 31, 2024 |
| Research and development expenses | $21.633M | Decreased from $33.926M in 2024 for the nine months ended September 30, 2025 |
| General and administrative expenses | $33.188M | Increased from $26.615M in 2024 for the nine months ended September 30, 2025 |
| Self-Tender Offer | $27.0M | Potential amount for Topco Common Stock post-merger |
| Ordinary shares outstanding | 40,830,353 | As of October 30, 2025 |
| Net loss per share (basic) | $0.36 | For the three months ended September 30, 2025, up from $0.21 in 2024 |
| Revenue | $0 | for the six months ended June 30, 2025, indicating a clinical-stage company |
| Operating Horizon | 12 months | company's ability to fund operations beyond this period is a key risk |
| Filing Date | 20250425 | Date the DEF 14A was filed with the SEC. |
| Meeting Date | 20250610 | Date of the shareholder meeting for which this proxy statement is issued. |
| Fiscal Year End | 2024-12-31 | The period covered by the financial information in the proxy statement. |
| Reporting Period End Date | 20240930 | Indicates the end of the fiscal quarter covered by the report. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Barinthus Biotherapeutics PLC. (BRNS)?
Barinthus Biotherapeutics PLC. has 30 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 5 10-Q, 2 8-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BRNS filings?
Across 30 filings, the sentiment breakdown is: 2 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Barinthus Biotherapeutics PLC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Barinthus Biotherapeutics PLC. (BRNS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Barinthus Biotherapeutics PLC.?
Key financial highlights from Barinthus Biotherapeutics PLC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BRNS?
The investment thesis for BRNS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Barinthus Biotherapeutics PLC.?
Key executives identified across Barinthus Biotherapeutics PLC.'s filings include Enright, Brown, Griffiths, Jonathan Jonathan, Sarah Howell and 6 others.
What are the main risk factors for Barinthus Biotherapeutics PLC. stock?
Of BRNS's 23 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Barinthus Biotherapeutics PLC.?
Forward guidance and predictions for Barinthus Biotherapeutics PLC. are extracted from SEC filings as they are enriched.